EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study

José M Ruiz-Moreno, Luís Arias, Maximino J Abraldes, Javier Montero, Patricia Udaondo, RAMDEBURS study group

International Ophthalmology · 2021-10 · 41 (10) · 3427-3436

DOI: 10.1007/s10792-021-01906-x ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Ophthalmology, online erschienen am 10.06.2021. Verfasst von José M Ruiz-Moreno und 5 weiteren Autor:innen. Beteiligte Einrichtung: Puerta de Hierro-Majadahonda University Hospital, Joaquín Rodrigo, 2 Majadahonda, 28222, Madrid, Spain. josemaria.ruiz@uclm.es. Hauptthemen laut MEDLINE: Macular Degeneration, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To describe and evaluate the main direct health costs, in routine clinical practice, of age-related macular degeneration (AMD) patients, from hospital perspective, in Spain.

Methods

Retrospective, multicenter, and observational study conducted on five third-level Spanish hospitals, between December 2018 and December 2019. The study included patients who were diagnosed of AMD before December 2018. Direct healthcare costs were obtained from a Spanish database. Study variables included demographic and clinical variables, and resources, such as treatment, diagnostic tests, medical examination, and surgery. Among the 1414 screened AMD patients, 1164 patients were included. In the overall study patients, the total cost was €5,386,511.0, with a mean cost per patient of €4627.6 ± 2383.9. The largest cost items were diagnostic examinations (€2.832.902,0) and vascular endothelial growth factor inhibitors (anti-VEGF) treatment (€2.038.257,2). Bevacizumab was administered to 325 (27.9%) patients, ranibizumab to 328 (28.2%), and aflibercept to 626 (53.8%); 115 (10.7%) patients received two anti-VEGF treatments, while 90 (7.7%) did not receive any. Over the course of the study, a total of 6,057 anti-VEGF injections were administered, with a mean (95% confidence interval) of 4.8 (4.4–5.2) injections per patient. Regarding safety, 29 patients experience injection-related adverse events, among them 12 patients had cataract and 11 ones elevated intraocular pressure (IOP). The incidence of endophthalmitis was 0.5% (6/1164).

Conclusions

AMD was associated with considerable healthcare costs for regional healthcare systems. Diagnostic examinations, particularly OCT examinations, and anti-VEGF treatment represented the largest cost items.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular DegenerationVascular Endothelial Growth Factor AAngiogenesis InhibitorsBevacizumabCost of IllnessHumansIntravitreal InjectionsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetrospective StudiesVisual Acuity

Stichwörter der Autor:innen

Age-related macular degenerationEconomic burdenHealth economicsVEGFVascular endothelial growth factor inhibitors

Substanzen

Angiogenesis InhibitorsRecombinant Fusion ProteinsVascular Endothelial Growth Factor ABevacizumabReceptors, Vascular Endothelial Growth FactorRanibizumab

Autor:innen und Institutionen

  • Puerta de Hierro-Majadahonda University Hospital, Joaquín Rodrigo, 2 Majadahonda, 28222, Madrid, Spain. josemaria.ruiz@uclm.es.
  • Department of Ophthalmology, Castilla La Mancha University, Albacete, Spain. josemaria.ruiz@uclm.es.
  • Red Temática de Investigación Cooperativa en Salud: "Prevención, detección precoz, y Tratamiento de La Patología Ocular Prevalente, Degenerativa Y Crónica" (RD16/0008/0021), Spanish Ministry of Health, Instituto de Salu…
  • , Miranza, Spain. josemaria.ruiz@uclm.es.
  • Bellvitge University Hospital, Barcelona, Spain.
  • Santiago de Compostela University Hospital Complex, A Coruña, Spain.

Förderung

  • Allergan

Zitieren

APA

Ruiz-Moreno, J. M., Arias, L., Abraldes, M. J., Montero, J., Udaondo, P., & RAMDEBURS study group (2021). Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study. International Ophthalmology, 41(10), 3427-3436. https://doi.org/10.1007/s10792-021-01906-x

Vancouver

Ruiz-Moreno JM, Arias L, Abraldes MJ, Montero J, Udaondo P, RAMDEBURS study group. Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study. International Ophthalmology. 2021;41(10):3427-3436. doi:10.1007/s10792-021-01906-x

BibTeX
@article{RuizMoreno2021,
  author = {Ruiz-Moreno, José M and Arias, Luís and Abraldes, Maximino J and Montero, Javier and Udaondo, Patricia and RAMDEBURS study group, RAMDEBURS study group},
  title = {Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study},
  journal = {International Ophthalmology},
  year = {2021},
  volume = {41},
  number = {10},
  pages = {3427--3436},
  doi = {10.1007/s10792-021-01906-x}
}
Kostenlos starten →